Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer

NCT03723928 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03723928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03723928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Lead sponsor
SWOG Cancer Research Network
Phase
Not applicable
Overall status
Recruiting
Start date
September 17, 2018
Completion date
December 1, 2036
Enrollment
739 (estimated)
Sites
723

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, elevated ca15-3 or cea or ca27-29, estrogen receptor positive, her2/neu negative, progesterone receptor positive, prognostic stage iv breast cancer ajcc v8